Abstract:In this study, we conducted a targeted siRNA screening and identified TATA box‐binding protein‐associated factor, TAF1D, as a critical regulator of the cell cycle and proliferation in high‐risk neuroblastoma cells in vivo and in vitro. Mechanistically, we demonstrate that TAF1D knockdown downregulates the expression of a set of G2/M phase‐related genes, including the master cell cycle kinase, cyclin‐dependent kinase 1 (CDK1), and leads to G2/M arrest. Thus, our work describes a novel cell‐cycle regulatory function of TAF1D in MYCN‐amplified HR‐NB that warrants further investigation as a potential therapeutic target and biomarker for high‐risk neuroblastoma. High‐risk neuroblastoma (HR‐NB) is an aggressive childhood cancer that responds poorly to currently available therapies and is associated with only about a 50% 5‐year survival rate. MYCN amplification is a critical driver of these aggressive tumors, but so far there have not been any approved treatments to effectively treat HR‐NB by targeting MYCN or its downstream effectors. Thus, the identification of novel molecular targets and therapeutic strategies to treat children diagnosed with HR‐NB represents an urgent unmet medical need. Here, we conducted a targeted siRNA screening and identified TATA box‐binding protein‐associated factor RNA polymerase I subunit D, TAF1D, as a critical regulator of the cell cycle and proliferation in HR‐NB cells. Analysis of three independent primary NB cohorts determined that high TAF1D expression correlated with MYCN‐amplified, high‐risk disease and poor clinical outcomes. TAF1D knockdown more robustly inhibited cell proliferation in MYCN‐amplified NB cells compared with MYCN‐non‐amplified NB cells, as well as suppressed colony formation and inhibited tumor growth in a xenograft mouse model of MYCN‐amplified NB. RNA‐seq analysis revealed that TAF1D knockdown downregulates the expression of genes associated with the G2/M transition, including the master cell‐cycle regulator, cell‐cycle‐dependent kinase 1 (CDK1), resulting in cell‐cycle arrest at G2/M. Our findings demonstrate that TAF1D is a key oncogenic regulator of MYCN‐amplified HR‐NB and suggest that therapeutic targeting of TAF1D may be a viable strategy to treat HR‐NB patients by blocking cell‐cycle progression and the proliferation of tumor cells.

Dendritic cell factor 1 inhibits proliferation and migration and induces apoptosis of neuroblastoma cells by inhibiting the ERK signaling pathway

Overexpression of DCF1 inhibits glioma through destruction of mitochondria and activation of apoptosis pathway

TAF1D promotes proliferation by transcriptionally activating G2/M phase‐related genes in MYCN‐amplified neuroblastoma

Smoothened-Independent Activation of Hedgehog Signaling by Rearranged During Transfection Promotes Neuroblastoma Cell Proliferation and Tumor Growth

RDM1 promotes neuroblastoma growth through the RAS-Raf-MEK-ERK pathway.

N-myc Downstream Regulated Gene 1 Inhibition of Tumor Progression in Caco2 Cells.

XAF1 promotes neuroblastoma tumor suppression and is required for KIF1Bβ-mediated apoptosis

Diminished Cytolytic Activity of Γδ T Cells with Reduced DNAM-1 Expression in Neuroblastoma Patients.

TTF1 Suppresses Neuroblastoma Growth and Induces Neuroblastoma Differentiation by Targeting TrkA and the Mir-204/Trkb Axis

BI-D1870 Induces Mitotic Dysfunction and Apoptosis in Neuroblastoma by Regulating the PI3K-Akt-mTORC1 Signal Axis

BRD4 Inhibitor MZ1 Exerts Anti-Cancer Effects by Targeting MYCN and MAPK Signaling in Neuroblastoma.

NEAT1 Negatively Regulates Cell Proliferation and Migration of Neuroblastoma Cells by Mir-183-5p/foxp1 Via the ERK/AKT Pathway.

DEDC, a new flavonoid induces apoptosis via a ROS-dependent mechanism in human neuroblastoma SH-SY5Y cells

DFMO inhibition of neuroblastoma tumorigenesis

Runt-related transcription factor 1 promotes apoptosis and inhibits neuroblastoma progression in vitro and in vivo

The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma

CDC27-ODC1 Axis Promotes Metastasis, Accelerates Ferroptosis and Predicts Poor Prognosis in Neuroblastoma

Targeting KDM1A in Neuroblastoma with NCL-1 Induces a Less Aggressive Phenotype and Suppresses Angiogenesis

Circular RNA DGKB Promotes the Progression of Neuroblastoma by Targeting miR-873/GLI1 Axis

<scp>RDM</scp> 1 promotes neuroblastoma growth through the <scp>RAS</scp> –Raf– <scp>MEK</scp> – <scp>ERK</scp> pathway

Identification of NCAPG as an Essential Gene for Neuroblastoma Employing CRISPR-Cas9 Screening Database and Experimental Verification